

**Table S1.** Summary of model agreement and imaging parameters for all participants

<b>Pt</b>	<b>Whole V<sub>0</sub> [cm<sup>3</sup>]</b>	<b>Cystic V<sub>0</sub> [cm<sup>3</sup>]</b>	<b>FLAIR mean slice thickness (SD) [mm]</b>	<b>FLAIR mean slice spacing (SD) [mm]</b>	<b>2D nRMSE</b>	<b>Whole nRMSE</b>	<b>2D/ Whole nRMSE ratio</b>	<b>PR- SD agree</b>	<b>SD- PD agree</b>
1	41.1	5.8	4.9 (0.4)	3.9 (0.4)	2.48	2.23	1.11	Yes	Yes
3	55.7	2.3	5.0 (0.0)	4.0 (0.0)	6.27	1.32	4.74	No	Yes
4	52.2	0.0	4.5 (0.6)	4.3 (0.5)	7.48	2.97	2.52	Yes	No
5	18.6	1.1	4.5 (1.2)	4.5 (1.2)	4.62	0.79	5.83	Yes	No
8	146.0	11.4	5.0 (0.0)	4.5 (0.7)	N/A	N/A	N/A	N/A	N/A
11	0.9	0.0	3.4 (0.9)	3.2 (0.5)	6.44	1.81	3.56	Yes	No
12	11.4	0.4	4.0 (0.0)	4.0 (0.0)	5.98	1.05	5.70	No	N/A
13	14.7	1.3	4.0 (0.0)	4.0 (0.0)	1.05	0.41	2.55	Yes	N/A
14	41.0	0.0	4.0 (0.0)	4.0 (0.0)	6.30	1.98	3.18	Yes	No
15	5.9	0.0	1.2 (2.3)	2.0 (1.7)	13.88	1.72	8.08	Yes	Yes
16	8.6	1.2	0.2 (1.1)	1.3 (0.9)	N/A	N/A	N/A	N/A	N/A
17	63.7	21.5	4.1 (0.2)	4.0 (0.4)	14.72	2.83	5.21	Yes	N/A
18	12.9	0.0	3.8 (0.5)	3.6 (0.5)	6.61	0.87	7.58	Yes	Yes
19	47.9	0.5	0.0 (0.0)	1.0 (0.0)	6.57	2.94	2.23	Yes	No
20	29.6	0.0	4.0 (0.2)	4.0 (0.0)	18.80	1.51	12.43	No	No
21	85.5	1.3	4.2 (0.4)	4.1 (0.3)	17.78	1.41	12.58	Yes	Yes
22	10.5	1.4	0.0 (0.0)	1.0 (0.0)	7.10	1.10	6.47	Yes	N/A
24	34.5	5.0	4.9 (0.4)	4.9 (0.3)	4.95	1.12	4.41	Yes	Yes
25	26.8	0.6	5.0 (0.0)	4.0 (0.0)	3.86	0.82	4.73	Yes	N/A
26	7.1	0.7	5.9 (0.5)	4.9 (0.3)	3.42	0.44	7.78	No	N/A
27	10.4	1.7	4.0 (0.0)	4.0 (0.0)	5.92	1.40	4.24	Yes	N/A
28	37.7	6.6	6.0 (0.0)	5.0 (0.0)	2.61	0.63	4.16	Yes	N/A
29	19.0	1.7	4.8 (0.4)	4.5 (0.5)	6.08	0.87	6.97	No	Yes
30	32.8	0.0	5.7 (0.7)	4.8 (0.4)	11.46	2.04	5.62	No	N/A
31	42.2	0.0	5.0 (1.7)	4.2 (1.3)	18.08	1.67	10.81	No	No
32	12.8	0.0	0.6 (1.8)	1.5 (1.4)	6.55	2.50	2.62	Yes	Yes
33	44.0	0.0	5.0 (0.0)	5.0 (0.0)	N/A	N/A	N/A	N/A	N/A
35	65.8	1.3	4.0 (0.0)	4.0 (0.0)	N/A	N/A	N/A	N/A	N/A
36	21.4	0.8	3.0 (0.0)	3.0 (0.0)	N/A	N/A	N/A	N/A	N/A
37	10.0	4.1	5.7 (0.8)	4.8 (0.4)	2.75	0.33	8.38	No	No
38	26.6	8.3	6.0 (0.0)	5.0 (0.0)	N/A	N/A	N/A	N/A	N/A

Pt = participant; V<sub>0</sub> = initial volume; SD = standard deviation; nRMSE = normalized root mean squared error; PR-SD = transition from PR to SD; SD-PD = transition from SD to PD, \*N/A indicates absence of definitive tumor regrowth or insufficient data points for model fit


**Table S2.** Summary of all Wilcoxon Rank sum test p-values

	<b>PR-SD agree</b>	<b>SD-PD agree</b>
<b>Whole <math>V_0</math> [cm<sup>3</sup>]</b>	0.727	0.916
<b>Cystic <math>V_0</math> [cm<sup>3</sup>]</b>	0.727	0.189
<b>FLAIR mean slice thickness</b>	0.041	0.600
<b>FLAIR SD slice thickness</b>	0.930	0.637
<b>FLAIR mean slice spacing</b>	0.020	0.916
<b>FLAIR SD slice spacing</b>	0.600	1.000
<b>2D/Whole nRMSE ratio</b>	0.010	0.916

$V_0$  = initial volume; SD = standard deviation; nRMSE = normalized root mean squared error;  
PR-SD = transition from PR to SD; SD-PD = transition from SD to PD


**Figure S1.** 2D measurements and whole tumor segmentations with model-based treatment response curves. Line colors indicate the model-based assignment to either PR (blue), SD (yellow) or PD (red), and background colors reflect BT-RADS labels relative to the pre-treatment scan. Model fits are shown with 95% confidence interval, and the legend shows the obtained distribution for  $t_{v_{\min}}$  as medians with 95% confidence intervals.

**PARTICIPANT #1:** Low-grade astrocytoma (not otherwise specified)




\*In the 2D trajectory, the model-based SD to PD transition occurred at the last timepoint of evaluation. This transition is represented by a small red portion at the end of the trajectory line, which in this figure is masked by the overlying point that represents the 2D measurement at the last timepoint of evaluation.


**PARTICIPANT #3:** Pilocytic astrocytoma



**PARTICIPANT #4: Pilocytic astrocytoma**




**PARTICIPANT #5: Pleomorphic xanthoastrocytoma**







**PARTICIPANT #8: Pilocytic astrocytoma**



**PARTICIPANT #11: Pilocytic astrocytoma**




**PARTICIPANT #12: Ganglioglioma**




\*The right thalamic lesion did not meet minimal size criteria to be included in 2D or volumetric measurements.


**PARTICIPANT #13: Pilocytic astrocytoma**




**PARTICIPANT #14: Pilocytic astrocytoma**



**PARTICIPANT #15: Ganglioglioma**




**PARTICIPANT #16: Ganglioglioma**




\*No trend line was drawn as participant #16 had a trajectory that did not comply with model intended dynamics.


**PARTICIPANT #17: Pilocytic astrocytoma**



**PARTICIPANT #18: Pleomorphic xanthoastrocytoma**




**PARTICIPANT #19: Pilocytic astrocytoma**








**PARTICIPANT #20: Pilocytic astrocytoma**




Note: Tumor extended from foramen magnum into cerebellum. Cerebellar portion was best segmented on axial FLAIR while foramen magnum portion was best segmented on sagittal T2. Both volumes were added to obtain whole tumor volume. As RAPNO stipulates only one set of 2D measurements per lesion, it was not possible to choose a plane that captured the full extent of disease in both cerebellum and foramen magnum to include in 2D measurements.




**PARTICIPANT #21: Pilocytic astrocytoma**




**PARTICIPANT #22: Ganglioglioma**




**PARTICIPANT #24: Anaplastic astrocytoma (Grade 3)**



PARTICIPANT #25: Pilocytic astrocytoma




PARTICIPANT #26: Pilocytic astrocytoma







**PARTICIPANT #27: Diffuse astrocytoma (Grade 2)**




**PARTICIPANT #28: Malignant glioma (not otherwise specified)**




**PARTICIPANT #29:** Glioneuronal tumor with desmoplasia




**PARTICIPANT #30:** Malignant glioma (not otherwise specified)




**PARTICIPANT #31: Fibrillary astrocytoma**




**PARTICIPANT #32: Ganglioglioma**




**PARTICIPANT #33: Diffuse midline glioma (H3K27M mutant)**




**PARTICIPANT #35: Ganglioglioma**



**PARTICIPANT #36:** Glioblastoma (not otherwise specified)



**PARTICIPANT #37:** Ganglioglioma



PARTICIPANT #38: Pilocytic astrocytoma

